Factor VIII: Difference between revisions
mNo edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
= Factor VIII | == Factor VIII == | ||
[[File:F8 gene location.png|thumb|Location of the F8 gene on the X chromosome.]] | |||
'''Factor VIII''' is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, it is encoded by the '''F8''' gene located on the X chromosome. Deficiency or dysfunction of Factor VIII results in [[hemophilia A]], a genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. | |||
[[ | == Function == | ||
Factor VIII is a glycoprotein that circulates in the bloodstream in an inactive form. It is activated by [[thrombin]] during the coagulation cascade. Once activated, Factor VIII acts as a cofactor for Factor IXa, which, in the presence of calcium ions and phospholipids, converts Factor X to the activated form, Factor Xa. This is a crucial step in the coagulation cascade, leading to the formation of a blood clot. | |||
Factor VIII is | == Clinical Use == | ||
Factor VIII concentrates are used in the treatment of hemophilia A. These concentrates can be derived from human plasma or produced using recombinant DNA technology. The administration of Factor VIII is essential for managing bleeding episodes in patients with hemophilia A and for prophylactic treatment to prevent bleeding. | |||
== | === Plasma-Derived Factor VIII === | ||
Plasma-derived Factor VIII is obtained from donated human blood plasma. It undergoes rigorous screening and purification processes to ensure safety and efficacy. However, there is a risk of viral transmission, although this risk has been significantly reduced with modern purification techniques. | |||
Factor VIII is | === Recombinant Factor VIII === | ||
Recombinant Factor VIII is produced using genetically engineered cells that express the F8 gene. This method eliminates the risk of blood-borne pathogens and allows for a consistent supply of the protein. Recombinant Factor VIII is widely used in clinical practice due to its safety profile. | |||
== | == Genetic Aspects == | ||
The F8 gene is located on the X chromosome at Xq28. Mutations in this gene can lead to hemophilia A. Since the gene is located on the X chromosome, hemophilia A is an X-linked recessive disorder, primarily affecting males, while females are typically carriers. | |||
== History == | |||
The discovery of Factor VIII and its role in coagulation was a significant milestone in hematology. The development of Factor VIII concentrates revolutionized the treatment of hemophilia A, transforming it from a debilitating condition to a manageable disorder. | |||
== Also see == | |||
* [[Hemophilia A]] | |||
* [[Coagulation cascade]] | |||
* [[Recombinant DNA technology]] | |||
* [[Thrombin]] | |||
{{Blood proteins}} | |||
{{Coagulation}} | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Blood proteins]] | ||
[[Category:Coagulation system]] | |||
Latest revision as of 03:00, 11 December 2024
Factor VIII[edit]

Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, it is encoded by the F8 gene located on the X chromosome. Deficiency or dysfunction of Factor VIII results in hemophilia A, a genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
Function[edit]
Factor VIII is a glycoprotein that circulates in the bloodstream in an inactive form. It is activated by thrombin during the coagulation cascade. Once activated, Factor VIII acts as a cofactor for Factor IXa, which, in the presence of calcium ions and phospholipids, converts Factor X to the activated form, Factor Xa. This is a crucial step in the coagulation cascade, leading to the formation of a blood clot.
Clinical Use[edit]
Factor VIII concentrates are used in the treatment of hemophilia A. These concentrates can be derived from human plasma or produced using recombinant DNA technology. The administration of Factor VIII is essential for managing bleeding episodes in patients with hemophilia A and for prophylactic treatment to prevent bleeding.
Plasma-Derived Factor VIII[edit]
Plasma-derived Factor VIII is obtained from donated human blood plasma. It undergoes rigorous screening and purification processes to ensure safety and efficacy. However, there is a risk of viral transmission, although this risk has been significantly reduced with modern purification techniques.
Recombinant Factor VIII[edit]
Recombinant Factor VIII is produced using genetically engineered cells that express the F8 gene. This method eliminates the risk of blood-borne pathogens and allows for a consistent supply of the protein. Recombinant Factor VIII is widely used in clinical practice due to its safety profile.
Genetic Aspects[edit]
The F8 gene is located on the X chromosome at Xq28. Mutations in this gene can lead to hemophilia A. Since the gene is located on the X chromosome, hemophilia A is an X-linked recessive disorder, primarily affecting males, while females are typically carriers.
History[edit]
The discovery of Factor VIII and its role in coagulation was a significant milestone in hematology. The development of Factor VIII concentrates revolutionized the treatment of hemophilia A, transforming it from a debilitating condition to a manageable disorder.
Also see[edit]
| Proteins involved in coagulation | ||||||
|---|---|---|---|---|---|---|
|